Advanced search
Publication Cover
International Review of Psychiatry Volume 14, 2002 - Issue 4: Recovery from schizophrenia: a challenge for the 21st century
Submit an article Journal homepage
24
Views
6
CrossRef citations to date
0
Altmetric
Research Article

The role of maintenance pharmacotherapy in achieving recovery from a first episode of schizophrenia

Sitra Tauscher-Wisniewski Schizophrenia and Continuing Care Program, Centre for Addiction and Mental Health,Toronto Department of Psychiatry, University of Toronto, Canada
&
Robert B. Zipursky Schizophrenia and Continuing Care Program, Centre for Addiction and Mental Health,Toronto Department of Psychiatry, University of Toronto, Canada
Pages 284-292 | Published online: 11 Jul 2009

  • AMERICAN PSYCHIATRIC ASSOCIATION. (1997). Practice guideline for the treatment of patients with schizophrenia [see comments]. American Journal of Psychiatry, 154 (4 Suppl), 1-63.
  • BEISER, M., ERICKSON, D., FLEMING, J.A. & IACONO, W.G. (1993). Establishing the onset of psychotic illness. American Journal of Psychiatry, 150, 1349-1354.
  • CANADIAN PSYCHIATRIC ASSOCIATION. (1998). Canadian clinical practice guidelines for the treatment of schizophrenia [see comments]. Canadian Journal of Psychiatry, 43 (Suppl 2), 25S-40S.
  • CARPENTER, W.T. JR., HANLON,T.E., HEINRICHS, D.W., SUMMERFELT, A.T., KIRKPATRICK, B., LEVINE, J. & BUCHANAN, R.W. (1990). Continuous versus targeted medication in schizophrenic outpatients: outcome results [published erratum appears in American Journal of Psychiatry (1991), 148, 819] [see comments]. American Journal of Psychiatry, 147, 1138-1148.
  • CASEY, D.E. (1995). Motor and mental aspects of extrapyramidal syndromes. International Clinical Psychopharmacology, 10 (Suppl 3), 105-114.
  • CHAKOS, M.H., ALVIR, J.M., WOERNER, M.G., KOREEN, A., GEISLER, S., MAYERHOFF, D, SOBEL, S., KANE, J.M., BORENSTEIN, M. & LIEBERMAN, J.A. (1996). Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 55,313-319.
  • CROW, T.J., MACMILLAN, J.F., JOHNSON, A.L. & JOHNSTONE, E.G. (1986). A randomized controlled trial of prophylactic neuroleptic treatment British Journal of Psychiatry, 148, 120-127.
  • DAVIDSON, L. & MCGLASHAN, T.H. (1997). The varied outcomes of schizophrenia. Canadian Journal of Psychiatry, 42, 34-43.
  • DOHRENWEND, B.P., DOLL, W, LINK, B., NEUGEBAUER, R. & WUSCH-HTTZIG, R (1980). Mental illness in the US. Epidemiologie estimates. New York: Praeger Publishers.
  • ENDICOTT,J. & SPITZER, R.L. (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry, 35, 837-844.
  • EXPERT CONSENSUS PANEL FOR SCHIZOPHRENIA (1996). Treatment of schizophrenia. Journal of Clinical Psychiatry, 57 (Suppl 12B), 3-58.
  • GAEBEL, W. (1994). Intermittent medication--an alternative? Acta Psychiatrica Scandinavica, 382 (Suppl), 33-38.
  • GLAZER, WM. (2000). Expected incidence of tardive dyskinesia associated with atypical antipsychotics. Journal of Clinical Psychiatry, 61 (Suppl 4), 21-26.
  • GOEREE, R., O'BRIEN, B.J., GOERING, P., BLACKHOUSE, G., AGRO, K., RHODES, A. & WATSON, J. (1999). The economic burden of schizophrenia in Canada. Canadian Journal of Psychiatry, 44, 464-472.
  • HAFNER, H. & AN DER HEiDEN, W. (1997). Epidemiology of schizophrenia [see comments]. Canadian Journal of Psychiatry, 42, 139-151.
  • HAFNER, H., MAURER, K., LOFFLER, W, AN DERHEIDEN, W., MUNK-JORGENSEN, P., HAMBRECHT, M.& RIECHER-ROSSLER, A. (1998). The ABC Schizophrenia Study, a preliminary overview of the results. Social Psychiatry and Psychiatric Epidemiology, 33, 380-386.
  • HERZ, M.I., GLAZER, W.M., MOSTERT, M.A., SHEARD, M.A., SZYMANSKI, H.V., HAFEZ, H., MIRZA, M., & VANA, J. (1991). Intermittent vs. maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry, 48, 333-339.
  • Ho, B.C., MILLER, D, NOPOULOS, P. & ANDREASEN, N.C. (1999). A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Journal of Clinical Psychiatry, 60, 658-663.
  • HOGARTY, G.E. & ULRICH, R.F. (1977). Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry, 34, 297-301.
  • HOGARTY, G.E. & ULRICH, R.F. (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research, 32, 243-250.
  • JABLENSKY, A., SARTORIUS, N., ERNBERG, G., ANKER, M., KORTEN, A., COOPER, J.E., DAY, R. & BERTELSEN, A. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization -country study (published erratum appears in Psychological Medicine, 20 [Suppl], following 1092). Psychological Medicine, 20 (Suppl), 1-97.
  • JOLLEY, A.G., HIRSCH, S.R., McRINK, A. & MANCHANDA, R. (1989).Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Medical Journal, 298, 985-990
  • KANE, J.M., RIFKIN, A., QUITKIN, R, NAYAK, D. & RAMOS-LORENZI, J. (1982). Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry, 39, 70-73.
  • KANE, J.M., WOERNER, M. & LIEBERMAN, J. (1988). Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8 (Suppl 4), 52S-56S.
  • KAPUR, S., REMINGTON, G., JONES, C., WILSON, A., DASILVA, J., HOULE, S. & ZIPURSKY, R. (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study [see comments]. American Journal of Psychiatry, 153, 948-950.
  • KAPUR, S., ZIPURSKY, R., JONES, C., REMINGTON, G. & HOULE, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a doubleblind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514-520.
  • KISSLING, W. & LEUCHT, S. (1999). Results of treatment of schizophrenia: is the glass half full or half empty? International Clinical Psychopharmacology, 14 (Suppl 3), S11-S14.
  • KOPALA, LC., GOOD, K.F., FREDERIKSON, D, WHITEHORN, D, LAZIER, L. & HONER, W.G. (1998). Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. International Journal of Psychiatry in Clinical Practice, 2 (Suppl 1), S19-S25.
  • LEHMAN, A.F. & STEINWACHS, D.M. (1998).Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10.
  • LIEBERMAN, J.A. (1993). Prediction of outcome in firstepisode schizophrenia. Journal of Clinical Psychiatry, 54 (Suppl), 13-17.
  • LIEBERMAN, J.A., ALVIR, J.M., KOREEN, A., GEISLER, S., CHAKOS, M., SHEITMAN, B. & WOERNER, M. (1996). Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14 (Suppl 3), 13S-21S.
  • LIEBERMAN, J.A., SALTZ, B.L., JOHNS, C.A., POLLACK, S., BORENSTEIN, M. & KANE, J. (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503-510.
  • LINDSTROM, E., ERIKSSON, B., HELLGREN, A., VON KNORRING, L. & EBERHARD, G. (1995). Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics, 17, 402-412.
  • LITTRELL, K.H., JOHNSON, G.G., LITTRELL, S. & PEABODY, C.D. (1998). Marked reduction of tardive dyskinesia with olanzapine [letter]. Archives of General Psychiatry, 55, 279-280.
  • LOEBEL, A.D., LIEBERMAN, J.A., ALVIR, J.M., MAYERHOFF, D.I., GEISLER, S.H. & SZYMANSKI, S.R. (1992). Duration of psychosis and outcome in firstepisode schizophrenia. American Journal of Psychiatry, 149,1183-1188.
  • MARDER, S.R. & MEIBACH, R.C. (1994). Risperidone in the treatment of schizophrenia [see comments]. American Journal of Psychiatry, 151,825-835.
  • McEvoY, J.P., HOGARTY, G.E. & STEINGARD, S. (1991). Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739-745.
  • McGLASHAN, T.H. (1984). The Chestnut Lodge followup study. II. Long-term outcome of schizophrenia and the affective disorders. Archives of General Psychiatry, 41, 586-601.
  • McGLASHAN, T-H. (1988). A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophrenia Bulletin, 14, 515-542
  • MELKERSSON, K.I., HULTING, A.L. & BRISMAR, K.E. (1999). Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Journal of Clinical Psychiatry, 60, 783-791.
  • MURRAY, C.J.L. & LOPEZ, A.D. (1996). The global burden of disease. Boston: Harvard School of Public Health.
  • RABINER, C.J., WEGNER, J.T. & KANE, J.M. (1986). Outcome study of first-episode psychosis. I: Relapse rates after 1 year. American Journal of Psychiatry, 143, 1155-1158.
  • REGIER, D.A., BOYD, J.H., BURKE, J.D., JR., RAE, D.S., MYERS, J.K., KRAMER, M., ROBINS, L.N., GEORGE, L.K., KARNO, M. & LOCKE, B.Z. (1988). One-month prevalence of mental disorders in the United States. Based on five Epidemiologie Catchment Area sites. Archives of General Psychiatry, 45,977-986.
  • RICE, DP. & MILLER, KS-(1996). The economic burden of schizophrenia: conceptual and methodological issues and cost estimates. In: M. MOSCARRELLI, A. RUFF & N. SARTORIUS (Eds.), Schizophrenia, Volume 1. (pp. 321-334). NewYork: John Wiley.
  • RICE, D.P. (1999). The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60 (Suppl 1), 4-6; discussion 28-30.
  • ROBINSON, D., WOERNER, M.G., ALVIR, J.M., BILDER, R., GOLDMAN, R., GEISLER, S., KOREEN, ., SHEITMAN, B., CHAKOS, M., MAYERHOFF, D., LIEBERMAN, J. A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoafiective disorder. Archives of General Psychiatry, 56, 241-247.
  • TAMMINGA, C.A., THAKER, O.K., MORAN, M., KAKIGI, T, GAO, X.M. (1994). Clozapine in tardive dystinesia: observations from human and animal model studies. Journal of Clinical Psychiatry, 55 (Suppl B), 102-106.
  • TRAN, P.V., DELLVA, M.A., TOLLEFSON, G.D., WENTLEY, A.L & BEASLEY, C.M., JR. (1998). Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry, 172, 499-505.
  • WASYLENKI, D.A. (1994). The cost of schizophrenia. Canadian Journal of Psychiatry, 39 (9, Suppl 2), S65-S69.
  • WIRSHING, D.A., SPELLBERG, B.J., ERHART, S.M., MARDER, SR. & WIRSHING, WC. (1998). Novel antipsychotics and new onset diabetes. Biological Psychiatry, 44, 778-783.
  • WOERNER, M.G., KANE, J.M., LJEBERMAN, J.A., ALVIR, J., BERGMANN, K.J., BORENSTEIN, M., SCHOOLER, N.R., MUKHERJEE, S., ROTROSEN, J., RUBINSTEIN, M. & BASAVARAJU, N. (1991).The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology, 11, 34-42.
  • ZHANG-WONG, J., ZIPURSKY, R.B., BEISER, M. & BEAN, G. (1999). Optimal haloperidol dosage in first-episode psychosis. Canadian Journal of Psychiatry, 44,164-167.
  • ZIPURSKY, R.B. & DARBY, P. (1999). Placebo-controlled studies in schizophrenia--ethical and scientific perspectives: an overview of conference proceedings. Schizophrenia Research, 35,189-200.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.